Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 5, 2010

Evotec and Argenta Sign New Drug Discovery Deals with Shionogi and Janssen

  • German firm Evotec and U.K.-based Argenta Discovery separately reported signing drug discovery agreements with new partners. Evotec is teaming up with Shionogi to identify small molecule modulators of various protein-protein interaction targets. The Galapagos subsidiary, Argenta, inked a cancer-focused drug discovery services agreement with Janssen Pharmaceutica.

    The deal between Shionogi and Evotec will see the latter apply its EVOlution™ fragment-based discovery platform to investigate protein-protein interactions on targets selected by Shionogi. The initially five-year deal between Argenta and Janssen could be worth over €33.5 million (about $45 million) to parent firm Galapagos. Under the terms of this deal, Argenta will provide medicinal chemistry and biology services for a number of Janssen’s oncology targets, along with hit-to-lead and lead-optimization activities and additional drug discovery work up to preclinical candidate selection. Janssen also retains the option to extend the partnership up to a total of 15 targets.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »